3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Lymphoma
8
Lymphoma, Extranodal NK-T-Cell
6
Neoplasm Metastasis
3
Sarcoma
2
Lymphoma, Large B-Cell, Diffuse
2
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
3
temsirolimus
1
spartalizumab
1
poly ICLC
1
patritumab
1
durvalumab
1
atezolizumab
1
advexin
1
Tetanus Toxoid
1
Sunitinib
1
Rifampin
1
Radiation
1
Nivolumab
1
Midazolam
1
Ketoconazole
1
Ipilimumab
1
Interleukin-15
1
Brentuximab Vedotin
1
Blood Specimen Collection
1
Axitinib
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
spartalizumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts